Tyrosine kinase inhibitors (TKIs) such as Imatinib mesylate (IM) which inhibit BCR-ABL kinase activity are used as frontline drug for chronic phase CML (CP-CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.